• Intressa Vascular

  Participated · Equity · Oct 2022

  Intressa Vascular (formerly Cardiatis SA) is a clinical-stage MedTech company based in Gembloux, Belgium. It has developed a proprietary braiding technology platform that produces multilayer stents. Its lead product, the Allay™ Aortic Stent, is designed to treat Type B aortic dissections (TBAD) and residual dissections by recentralizing blood flow inside the true lumen while preserving branch perfusion via a streamlined procedure. The company is led by CEO Pierre Douette and CSO Diane Lejeune. Intressa intends to use recent financing to support clinical development and product registration activities and to further anchor and develop the organization locally. The company recently completed an €18m financing package to advance these objectives.

• I-care Group

  Led · Equity · Sep 2022

  Founded in 2004, I-care Group develops hardware sensors and an AI-powered software platform that monitor industrial equipment to predict failures and optimize maintenance. Its subscription-based Wi-care as a Service offering combines in-house–manufactured vibration sensors (capacity up to 2,000 units per day) with the I-see platform, which already tracks data from more than 150,000 sensors worldwide. The company has grown into an international organization with 36 offices across 16 countries and serves customers in over 55 nations. I-care reports consolidated annual revenue exceeding €100 million, an order book above €200 million, and a workforce of more than 1,000 employees. Management is executing a three-phase growth plan that includes the current internal financing, a larger external investor round targeted for 2026, and an eventual IPO. Over the past eight years, I-care has completed eight acquisitions to expand its reach and capabilities. The firm’s heavy investment in R&D and early bet on AI underpin its competitive edge in the rapidly expanding predictive maintenance market.

• OncoDNA

  Participated · Series B · Feb 2020

  OncoDNA combines advanced testing of clinically relevant cancer biomarkers (DNA, RNA and protein) from solid and liquid biopsies with a proprietary cancer treatment knowledge database to deliver one‑stop analysis and interpretation services. Its web‑based OncoKDM software processes raw NGS data to generate clinical insights such as treatment options and clinical‑trial matches for oncologists. The company also licenses its interpretation software to molecular laboratories and collaborates with biopharma on clinical‑trial design, enrollment and assessment. OncoDNA completed a €19 million Series B equity financing to support rapid international growth, accelerate software development and expand hiring. The company aims to become the European leader in oncogenomic data interpretation and to connect molecular laboratories to its advanced interpretation tools. OncoDNA is based in Gosselies, Belgium, employs 50 people across four countries, has an international network of 35 distributors covering approximately 50 countries, and collaborates with a subcontracted laboratory of about 300 collaborators. OncoDNA is a precision medicine company based in Gosselies, Belgium, that provides molecular and proteomic analyses to guide cancer treatment decisions. Led by CEO Jean-Pol Detiffe, the company supports oncologists daily in finding treatment options for advanced cancer patients. Its product suite includes OncoDEEP (DNA sequencing and protein analyses of solid biopsies), OncoDEEP&TRACE (combined solid tumour and liquid biopsy analyses), OncoTRACE (a blood-based tumor monitoring solution), and OncoSHARE (sample logistics, ordering, process follow-up, data analysis and sharing). The company closed a €7.7M equity financing round and intends to use the proceeds to further accelerate global market expansion. No revenue or user metrics were disclosed in the article.

No current team members are available.